Cellectis, a clinical-stage biotech company specializing in gene-editing therapies, announced it will report its financial results for the first quarter of 2026 on May 11, after the US market closes. The company, known for its allogeneic CAR T-cell therapies for cancer and gene therapy platforms, will publish the results on its website but will not hold a conference call. Investors can direct questions to the company's investor relations team. This update is important as it provides insight into the company's financial health and progress in its pioneering gene-editing treatments.
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...
Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...
